Alex Mercer
Stockholm, AB, Sweden
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Early Change in Proteinuria as a Surrogate Endpoint in Studies of IgA Nephropathy: An Updated Patient-Level Meta-analysis and Discussion of Appropriate Methodology.
Journal: Advances in therapy
Published: September 03, 2025
Authors' Reply: Questions Regarding the Analysis of Long-Term Outcomes in Nephrotic Syndrome.
Journal: Journal of the American Society of Nephrology : JASN
Published: August 04, 2025
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 07, 2025
Association between Complete Proteinuria Remission and Kidney Function in the Phase 3 PROTECT Trial of Sparsentan in IgA Nephropathy.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: July 07, 2025
Long-Term Outcomes in Nephrotic Syndrome by Kidney Biopsy Diagnosis and Proteinuria.
Journal: Journal of the American Society of Nephrology : JASN
Published: August 15, 2024
Long-term outcomes of patients with IgA nephropathy in the German CKD cohort.
Journal: Clinical kidney journal
Published: June 10, 2024
Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.
Journal: Clinical kidney journal
Published: January 19, 2024
Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.
Journal: The New England journal of medicine
Published: November 03, 2023
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Journal: Lancet (London, England)
Published: September 29, 2023
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Journal: Kidney international reports
Published: September 12, 2023
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.
Journal: Lancet (London, England)
Published: February 28, 2023
IgA Nephropathy Patient Baseline Characteristics in the Sparsentan PROTECT Study.
Journal: Kidney international reports
Published: November 30, 2022
Last Updated: 09/26/2026